captopril has been researched along with Cognitive Decline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Dong, X; Fan, J; Gong, L; He, D; Jiang, J; Jiang, P; Kuang, H; Kuang, R; Lin, D; Shen, W; Wang, X; Xia, N; Xie, Y; Zeng, L | 1 |
| Abd El-Latif, HA; El-Yamany, MF; Georgy, GS; Youssef, MM | 1 |
2 other study(ies) available for captopril and Cognitive Decline
| Article | Year |
|---|---|
Captopril alleviates epilepsy and cognitive impairment by attenuation of C3-mediated inflammation and synaptic phagocytosis.
Topics: Animals; Captopril; Cognitive Dysfunction; Epilepsy; Inflammation; Kainic Acid; Phagocytosis; Rats; Rats, Sprague-Dawley | 2022 |
Aliskiren and captopril improve cognitive deficits in poorly controlled STZ-induced diabetic rats via amelioration of the hippocampal P-ERK, GSK3β, P-GSK3β pathway.
Topics: Amides; Animals; Avoidance Learning; Brain; Captopril; Cholinesterases; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Fumarates; Glycogen Synthase Kinase 3; Hippocampus; Interleukin-1beta; Male; MAP Kinase Signaling System; Maze Learning; Pancreas; Rats; Rats, Sprague-Dawley; Recognition, Psychology | 2020 |